Last reviewed · How we verify
Gynomunal® gel — Competitive Intelligence Brief
marketed
Vaginal probiotic/microbiota restorer
Gynecology
Small molecule
Live · refreshed every 30 min
Target snapshot
Gynomunal® gel (Gynomunal® gel) — Derming SRL. Gynomunal® gel is a topical vaginal preparation designed to restore and maintain healthy vaginal microbiota and mucosal integrity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gynomunal® gel TARGET | Gynomunal® gel | Derming SRL | marketed | Vaginal probiotic/microbiota restorer |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Vaginal probiotic/microbiota restorer class)
- Derming SRL · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gynomunal® gel CI watch — RSS
- Gynomunal® gel CI watch — Atom
- Gynomunal® gel CI watch — JSON
- Gynomunal® gel alone — RSS
- Whole Vaginal probiotic/microbiota restorer class — RSS
Cite this brief
Drug Landscape (2026). Gynomunal® gel — Competitive Intelligence Brief. https://druglandscape.com/ci/gynomunal-gel. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing